lacosamide Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	4310	175481-36-4

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: ertosamide SPM-927 lacosamide erlosamide harkoseride vimpat	a functionalized amino acid, selectively enhances slow inactivation of voltage-gated sodium channels, resulting in stabilization of hyperexcitable neuronal membranes and inhibition of repetitive neuronal firing, indicated for partial-onset seizures Molecular weight: 250.30 Formula: C13H18N2O3 CLOGP: 0.39 LIPINSKI: 0 HAC: 5 HDO: 2 TPSA: 67.43 ALOGS: -2.73 ROTB: 6 Status: ONP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

ertosamide
SPM-927
lacosamide
erlosamide
harkoseride
vimpat

a functionalized amino acid, selectively enhances slow inactivation of voltage-gated sodium channels, resulting in stabilization of hyperexcitable neuronal membranes and inhibition of repetitive neuronal firing, indicated for partial-onset seizures

Molecular weight: 250.30
Formula: C13H18N2O3
CLOGP: 0.39
LIPINSKI: 0
HAC: 5
HDO: 2
TPSA: 67.43
ALOGS: -2.73
ROTB: 6

Status: ONP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.30	g	O
0.30	g	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	2 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	40 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	22.83 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution)	0.58 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	0.57 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.85 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	12.30 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Aug. 29, 2008	EMA
Oct. 28, 2008	FDA	UCB INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Seizure	1926.86	17.34	924	16331	122130	46546677
Status epilepticus	1045.84	17.34	329	16926	13650	46655157
Epilepsy	665.97	17.34	270	16985	23468	46645339
Generalised tonic-clonic seizure	502.04	17.34	230	17025	26892	46641915
Multiple-drug resistance	418.98	17.34	111	17144	2454	46666353
Off label use	410.75	17.34	595	16660	379246	46289561
Overdose	241.32	17.34	239	17016	101740	46567067
Partial seizures	223.30	17.34	80	17175	4930	46663877
Focal dyscognitive seizures	221.28	17.34	69	17186	2759	46666048
Diplopia	173.57	17.34	101	17154	19304	46649503
Drug ineffective	169.31	17.34	590	16665	677248	45991559
Pregnancy	166.17	17.34	111	17144	27026	46641781
Petit mal epilepsy	108.91	17.34	42	17213	3178	46665629
Electrocardiogram QRS complex prolonged	99.98	17.34	46	17209	5403	46663404
Irritability	93.82	17.34	81	17174	28865	46639942
Mitochondrial DNULL mutation	87.57	17.34	20	17235	231	46668576
Aura	85.00	17.34	26	17229	973	46667834
Propofol infusion syndrome	78.00	17.34	23	17232	758	46668049
Drug ineffective for unapproved indication	76.84	17.34	57	17198	16356	46652451
Pain	76.01	17.34	41	17214	476907	46191900
Somnolence	75.85	17.34	174	17081	156347	46512460
Atrioventricular block complete	74.32	17.34	42	17213	7585	46661222
Seizure cluster	72.07	17.34	16	17239	161	46668646
Drug interaction	71.52	17.34	200	17055	202894	46465913
Sudden unexplained death in epilepsy	69.30	17.34	17	17238	272	46668535
Maternal exposure during pregnancy	68.38	17.34	130	17125	102419	46566388
Diarrhoea	68.35	17.34	64	17191	559538	46109269
Maternal exposure before pregnancy	67.42	17.34	33	17222	4448	46664359
Balance disorder	67.37	17.34	100	17155	64421	46604386
Change in seizure presentation	65.23	17.34	16	17239	256	46668551
Arthralgia	64.69	17.34	27	17228	364576	46304231
Myoclonic epilepsy	61.78	17.34	20	17235	903	46667904
Neurotoxicity	60.56	17.34	46	17209	13671	46655136
Bradycardia	59.74	17.34	96	17159	66202	46602605
Gene mutation	58.69	17.34	20	17235	1060	46667747
Dyspnoea	58.30	17.34	63	17192	515485	46153322
Abortion spontaneous	58.03	17.34	76	17179	43570	46625237
Ataxia	57.75	17.34	45	17210	13885	46654922
Electroencephalogram abnormal	57.54	17.34	28	17227	3726	46665081
Premature delivery	54.40	17.34	53	17202	22016	46646791
Atrioventricular block	51.90	17.34	32	17223	6779	46662028
Encephalopathy	51.82	17.34	63	17192	33526	46635281
Drug reaction with eosinophilia and systemic symptoms	51.51	17.34	59	17196	29489	46639318
Electrocardiogram PR prolongation	51.21	17.34	16	17239	643	46668164
No adverse event	50.86	17.34	63	17192	34168	46634639
Angiofibroma	49.61	17.34	11	17244	110	46668697
Blood gases abnormal	47.53	17.34	15	17240	623	46668184
Drug resistance	47.16	17.34	44	17211	17324	46651483
Myoclonus	46.15	17.34	40	17215	14312	46654495
Psychotic disorder	46.06	17.34	49	17206	22572	46646235
Abnormal behaviour	45.34	17.34	47	17208	21011	46647796
Cardiac arrest	43.17	17.34	100	17155	90299	46578508
Unmasking of previously unidentified disease	41.54	17.34	14	17241	717	46668090
Aphasia	41.51	17.34	52	17203	28515	46640292
Lymphangioleiomyomatosis	40.31	17.34	10	17245	168	46668639
Pain in extremity	39.99	17.34	23	17232	258657	46410150
Memory impairment	39.64	17.34	88	17167	77249	46591558
Tonic convulsion	39.46	17.34	15	17240	1091	46667716
Joint swelling	39.27	17.34	7	17248	166066	46502741
Aggression	38.94	17.34	45	17210	22699	46646108
Angiomyolipoma	38.86	17.34	10	17245	196	46668611
Partial seizures with secondary generalisation	38.71	17.34	11	17244	317	46668490
Laryngeal stenosis	38.37	17.34	13	17242	677	46668130
Hyperammonaemic encephalopathy	37.20	17.34	17	17238	1965	46666842
Dizziness	36.73	17.34	233	17022	340181	46328626
Abdominal pain	36.20	17.34	20	17235	230011	46438796
Atonic seizures	35.73	17.34	12	17243	608	46668199
Cognitive disorder	35.40	17.34	55	17200	36828	46631979
Back pain	34.92	17.34	17	17238	210022	46458785
Respiratory acidosis	34.86	17.34	24	17231	6124	46662683
Behaviour disorder	34.24	17.34	16	17239	1945	46666862
Metabolic acidosis	33.34	17.34	55	17200	38725	46630082
Tremor	33.14	17.34	106	17149	115533	46553274
Cough	32.12	17.34	23	17232	230226	46438581
Lipids abnormal	31.14	17.34	9	17246	276	46668531
Sinus bradycardia	30.10	17.34	31	17224	13751	46655056
Hallucination, visual	29.99	17.34	35	17220	17838	46650969
Drug withdrawal convulsions	29.97	17.34	13	17242	1328	46667479
Abortion induced	29.81	17.34	27	17228	10233	46658574
Sinusitis	29.54	17.34	6	17249	129762	46539045
Myalgia	29.50	17.34	5	17250	123083	46545724
Stillbirth	29.16	17.34	22	17233	6469	46662338
Injection site pain	28.90	17.34	3	17252	107149	46561658
Disturbance in attention	28.82	17.34	46	17209	31514	46637293
Simple partial seizures	28.78	17.34	10	17245	562	46668245
Food interaction	28.61	17.34	10	17245	572	46668235
Hyperammonaemia	28.14	17.34	19	17236	4697	46664110
Dehydration	27.93	17.34	12	17243	159528	46509279
Atrioventricular block first degree	27.87	17.34	21	17234	6165	46662642
Anticonvulsant drug level decreased	27.61	17.34	12	17243	1232	46667575
Suicide attempt	27.49	17.34	62	17193	54974	46613833
Sinus node dysfunction	27.33	17.34	18	17237	4271	46664536
Infusion related reaction	26.87	17.34	3	17252	101205	46567602
Intrusive thoughts	26.79	17.34	7	17248	146	46668661
Acute kidney injury	26.35	17.34	29	17226	235826	46432981
Cardiotoxicity	26.32	17.34	21	17234	6701	46662106
Anticonvulsant drug level increased	26.08	17.34	12	17243	1408	46667399
Bronchitis	26.08	17.34	4	17251	105975	46562832
Therapeutic product effective for unapproved indication	26.06	17.34	6	17249	72	46668735
Encephalitis autoimmune	25.46	17.34	11	17244	1113	46667694
Drug hypersensitivity	25.08	17.34	32	17223	243793	46425014
Rhesus incompatibility	25.07	17.34	6	17249	86	46668721
Nystagmus	24.91	17.34	19	17236	5680	46663127
Anaemia	24.86	17.34	35	17220	255744	46413063
Electrocardiogram ST segment elevation	24.75	17.34	16	17239	3679	46665128
Therapeutic product ineffective for unapproved indication	24.66	17.34	7	17248	201	46668606
Frontal lobe epilepsy	24.37	17.34	4	17251	5	46668802
Electrocardiogram repolarisation abnormality	24.21	17.34	11	17244	1254	46667553
Intensive care unit acquired weakness	23.98	17.34	9	17246	632	46668175
Systolic dysfunction	23.81	17.34	11	17244	1303	46667504
Nausea	23.78	17.34	153	17102	687301	45981506
Maternal exposure during breast feeding	23.56	17.34	14	17241	2775	46666032
Musculoskeletal stiffness	23.44	17.34	4	17251	97989	46570818
Nasopharyngitis	23.34	17.34	14	17241	153984	46514823
Suicidal ideation	23.28	17.34	59	17196	56323	46612484
Peripheral swelling	23.08	17.34	15	17240	158056	46510751
Blood lactic acid increased	22.85	17.34	18	17237	5639	46663168
Directional Doppler flow tests abnormal	22.61	17.34	4	17251	10	46668797
Swelling	22.37	17.34	9	17246	124502	46544305
Intentional overdose	21.84	17.34	63	17192	64881	46603926
Febrile infection-related epilepsy syndrome	21.83	17.34	4	17251	13	46668794
Sedation	21.75	17.34	34	17221	22876	46645931
Drug level increased	21.29	17.34	30	17225	18411	46650396
Euthyroid sick syndrome	21.21	17.34	5	17250	67	46668740
Ventricular hypokinesia	20.98	17.34	15	17240	4063	46664744
Sinus arrest	20.93	17.34	11	17244	1720	46667087
Amnesia	20.90	17.34	47	17208	41584	46627223
Dysarthria	20.72	17.34	44	17211	37454	46631353
Lipids	20.29	17.34	4	17251	21	46668786
Head injury	19.92	17.34	34	17221	24602	46644205
Violence-related symptom	19.87	17.34	7	17248	410	46668397
Learning disorder	19.67	17.34	7	17248	422	46668385
QRS axis abnormal	19.66	17.34	9	17246	1044	46667763
Atrioventricular block second degree	19.60	17.34	14	17241	3785	46665022
Tachycardia	18.95	17.34	80	17175	99542	46569265
Chest discomfort	18.90	17.34	5	17250	90264	46578543
Arthritis	18.83	17.34	3	17252	77313	46591494
Ventricular fibrillation	18.44	17.34	22	17233	11474	46657333
Prescribed overdose	18.43	17.34	21	17234	10428	46658379
Arrhythmia	18.24	17.34	40	17215	34801	46634006
Drug level decreased	18.05	17.34	16	17239	5896	46662911
Intensive care unit delirium	17.95	17.34	4	17251	41	46668766
Calcinosis	17.93	17.34	10	17245	1759	46667048
Neonatal seizure	17.77	17.34	6	17249	309	46668498
Malaise	17.67	17.34	63	17192	331169	46337638
Asthma	17.48	17.34	6	17249	91536	46577271
Shock	17.47	17.34	30	17225	21815	46646992
Pneumonia aspiration	17.36	17.34	37	17218	31568	46637239

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Seizure	1611.70	17.78	813	12792	97662	29841211
Status epilepticus	652.32	17.78	229	13376	10843	29928030
Generalised tonic-clonic seizure	436.25	17.78	201	13404	19350	29919523
Epilepsy	327.89	17.78	167	13438	20002	29918871
Off label use	298.28	17.78	457	13148	248833	29690040
Partial seizures	292.65	17.78	96	13509	3671	29935202
Multiple-drug resistance	212.61	17.78	71	13534	2870	29936003
Drug ineffective	170.43	17.78	433	13172	339954	29598919
Aggression	145.35	17.78	126	13479	36781	29902092
Focal dyscognitive seizures	141.62	17.78	43	13562	1270	29937603
Sudden unexplained death in epilepsy	135.02	17.78	33	13572	417	29938456
Overdose	106.14	17.78	159	13446	84178	29854695
Somnolence	95.11	17.78	163	13442	96600	29842273
Petit mal epilepsy	81.07	17.78	34	13571	2597	29936276
Partial seizures with secondary generalisation	80.06	17.78	19	13586	210	29938663
Drug withdrawal convulsions	68.22	17.78	24	13581	1135	29937738
Aura	65.20	17.78	17	13588	283	29938590
Foetal exposure during pregnancy	62.00	17.78	80	13525	36791	29902082
Necrosis ischaemic	59.11	17.78	15	13590	223	29938650
Behaviour disorder	57.46	17.78	26	13579	2386	29936487
Cognitive disorder	57.44	17.78	62	13543	23628	29915245
Dyspnoea	55.98	17.78	42	13563	333253	29605620
Ataxia	55.17	17.78	44	13561	11418	29927455
Drug resistance	54.71	17.78	56	13549	20077	29918796
Nystagmus	53.69	17.78	30	13575	4308	29934565
Atrioventricular block complete	52.89	17.78	38	13567	8439	29930434
Seizure cluster	52.12	17.78	12	13593	115	29938758
Hyperammonaemia	49.50	17.78	31	13574	5489	29933384
No adverse event	48.32	17.78	49	13556	17370	29921503
Atrioventricular block second degree	48.04	17.78	25	13580	3115	29935758
Congenital hypoplasia of depressor angularis oris muscle	48.04	17.78	8	13597	8	29938865
Superinfection	46.87	17.78	20	13585	1594	29937279
Maternal exposure during pregnancy	45.82	17.78	26	13579	3845	29935028
Atrioventricular block	43.96	17.78	32	13573	7250	29931623
Brain operation	41.96	17.78	12	13593	286	29938587
Exposure via breast milk	40.82	17.78	18	13587	1554	29937319
Myoclonic epilepsy	40.71	17.78	15	13590	811	29938062
Irritability	40.28	17.78	51	13554	22999	29915874
Mucosal ulceration	39.82	17.78	15	13590	863	29938010
Postictal psychosis	38.13	17.78	9	13596	97	29938776
Intestinal ischaemia	36.48	17.78	28	13577	6869	29932004
Coarctation of the aorta	36.39	17.78	12	13593	465	29938408
Diarrhoea	36.39	17.78	60	13545	334043	29604830
Acoustic stimulation tests abnormal	35.40	17.78	8	13597	70	29938803
Bradycardia	33.03	17.78	84	13521	65442	29873431
Haemoglobin decreased	32.97	17.78	6	13599	114092	29824781
Drug ineffective for unapproved indication	32.74	17.78	32	13573	10848	29928025
Agitation	32.27	17.78	74	13531	53999	29884874
Pain	31.22	17.78	20	13585	172621	29766252
Encephalopathy	31.21	17.78	54	13551	32151	29906722
Premature baby	30.87	17.78	38	13567	16653	29922220
Anomaly of external ear congenital	30.80	17.78	8	13597	131	29938742
Depressive symptom	30.75	17.78	15	13590	1630	29937243
Drug interaction	29.71	17.78	173	13432	199395	29739478
Low birth weight baby	28.54	17.78	23	13582	6053	29932820
Hippocampal sclerosis	28.45	17.78	7	13598	91	29938782
Diplopia	28.16	17.78	33	13572	13739	29925134
Febrile neutropenia	27.98	17.78	7	13598	106686	29832187
Dizziness	27.74	17.78	167	13438	194742	29744131
Atrial septal defect	26.57	17.78	23	13582	6678	29932195
Change in seizure presentation	26.50	17.78	6	13599	53	29938820
Intellectual disability	26.39	17.78	11	13594	827	29938046
Congenital melanocytic naevus	26.09	17.78	5	13600	17	29938856
Glioblastoma	25.80	17.78	12	13593	1173	29937700
Arthralgia	24.17	17.78	16	13589	135775	29803098
Pneumonia	24.16	17.78	75	13530	334231	29604642
Abdominal pain	24.12	17.78	16	13589	135638	29803235
Pneumonia aspiration	23.98	17.78	53	13552	37727	29901146
Acute kidney injury	23.87	17.78	56	13549	273786	29665087
Psychotic disorder	23.41	17.78	38	13567	21477	29917396
Dissociation	23.17	17.78	11	13594	1126	29937747
Systemic inflammatory response syndrome	23.04	17.78	21	13584	6525	29932348
Unmasking of previously unidentified disease	22.78	17.78	9	13596	589	29938284
Speech disorder	22.32	17.78	40	13565	24472	29914401
Anger	21.67	17.78	26	13579	11094	29927779
Memory impairment	21.21	17.78	50	13555	37124	29901749
Brain oedema	20.97	17.78	27	13578	12371	29926502
Gastrointestinal haemorrhage	20.88	17.78	6	13599	83440	29855433
Hyperammonaemic encephalopathy	20.79	17.78	12	13593	1832	29937041
Psychogenic seizure	20.78	17.78	7	13598	290	29938583
Haematuria traumatic	20.23	17.78	6	13599	163	29938710
Abnormal behaviour	19.83	17.78	39	13566	25584	29913289
Renal failure	19.40	17.78	18	13587	128948	29809925
Hyperkinesia	19.36	17.78	12	13593	2086	29936787
Drug reaction with eosinophilia and systemic symptoms	19.25	17.78	41	13564	28447	29910426
Drug level decreased	19.22	17.78	18	13587	5787	29933086
Blood lactic acid increased	19.15	17.78	18	13587	5812	29933061
Bradycardia neonatal	19.09	17.78	9	13596	907	29937966
Bradykinesia	19.05	17.78	14	13591	3216	29935657
Periventricular haemorrhage neonatal	19.02	17.78	4	13601	24	29938849
Suicidal ideation	18.91	17.78	47	13558	36067	29902806
Hypothermia neonatal	18.60	17.78	5	13600	94	29938779
Brain neoplasm	18.59	17.78	13	13592	2764	29936109
Anaemia	18.53	17.78	42	13563	207950	29730923
Congenital aortic atresia	18.49	17.78	4	13601	28	29938845
Chills	18.47	17.78	5	13600	72333	29866540
Product availability issue	18.09	17.78	8	13597	695	29938178
Myoclonus	17.99	17.78	26	13579	13286	29925587
Thoracic vertebral fracture	17.93	17.78	10	13595	1430	29937443

Pharmacologic Action:

Source	Code	Description
ATC	N03AX18	NERVOUS SYSTEM ANTIEPILEPTICS ANTIEPILEPTICS Other antiepileptics
FDA PE	N0000008486	Decreased Central Nervous System Disorganized Electrical Activity
FDA EPC	N0000175753	Anti-epileptic Agent
MeSH PA	D000927	Anticonvulsants
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D049990	Membrane Transport Modulators
MeSH PA	D026941	Sodium Channel Blockers
MeSH PA	D061567	Voltage-Gated Sodium Channel Blockers

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Partial Epilepsy Treatment Adjunct	indication
Atrial flutter	contraindication	5370000
Suicidal thoughts	contraindication	6471006
Complete atrioventricular block	contraindication	27885002
Orthostatic hypotension	contraindication	28651003
Sick sinus syndrome	contraindication	36083008	DOID:13884
Chronic heart failure	contraindication	48447003
Atrial fibrillation	contraindication	49436004	DOID:0060224
Acute nephropathy	contraindication	58574008
Second degree atrioventricular block	contraindication	195042002
Disease of liver	contraindication	235856003	DOID:409
Suicidal	contraindication	267073005
Disorder of coronary artery	contraindication	414024009
Myocardial ischemia	contraindication	414795007	DOID:3393
Severe Cardiac Disease	contraindication
First Degree Atrioventricular Heart Block	contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	12.83	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Sodium channel protein type 9 subunit alpha	Ion channel	Q15858	SCN9A_HUMAN	BLOCKER	IC50	6.74	CHEMBL	CHEMBL
Carbonic anhydrase 2	Enzyme	P00918	CAH2_HUMAN		Ki	6.48	CHEMBL
Carbonic anhydrase 12	Enzyme	O43570	CAH12_HUMAN		Ki	5.43	CHEMBL
Carbonic anhydrase 4	Enzyme	P22748	CAH4_HUMAN		Ki	6.28	CHEMBL
Carbonic anhydrase 13	Enzyme	Q8N1Q1	CAH13_HUMAN		Ki	5.92	CHEMBL
Carbonic anhydrase 3	Enzyme	P07451	CAH3_HUMAN		Ki	6.43	CHEMBL
Carbonic anhydrase 5A, mitochondrial	Enzyme	P35218	CAH5A_HUMAN		Ki	5.34	CHEMBL
Carbonic anhydrase 14	Enzyme	Q9ULX7	CAH14_HUMAN		Ki	6.33	CHEMBL
Carbonic anhydrase 7	Enzyme	P43166	CAH7_HUMAN		Ki	5.35	CHEMBL
Carbonic anhydrase 9	Enzyme	Q16790	CAH9_HUMAN		Ki	6.45	CHEMBL
Carbonic anhydrase 1	Enzyme	P00915	CAH1_HUMAN		Ki	6.44	CHEMBL
Carbonic anhydrase 5B, mitochondrial	Enzyme	Q9Y2D0	CAH5B_HUMAN		Ki	6.47	CHEMBL
Carbonic anhydrase 6	Enzyme	P23280	CAH6_HUMAN		Ki	6.39	CHEMBL
Dihydropyrimidinase-related protein 2	Unclassified	Q16555	DPYL2_HUMAN				WOMBAT-PK
Sodium channel protein type X alpha subunit	Unclassified		SCNAA_RAT		IC50	4.80	CHEMBL
Sodium channel protein type 3 subunit alpha	Ion channel		SCN3A_RAT		IC50	6.38	CHEMBL
Carbonic anhydrase 15	Enzyme		CAH15_MOUSE		Ki	6.34	CHEMBL
Sodium channel protein type 2 subunit alpha	Ion channel		SCN2A_RAT	BLOCKER	IC50	4.52	IUPHAR

External reference:

ID	Source
4028103	VUID
N0000179735	NUI
D07299	KEGG_DRUG
4028103	VANDF
C0893761	UMLSCUI
CHEBI:135939	CHEBI
CHEMBL58323	ChEMBL_ID
DB06218	DRUGBANK_ID
D000078334	MESH_DESCRIPTOR_UI
C476828	MESH_SUPPLEMENTAL_RECORD_UI
219078	PUBCHEM_CID
7472	IUPHAR_LIGAND_ID
8094	INN_ID
563KS2PQY5	UNII
623400	RXNORM
158490	MMSL
25914	MMSL
d07349	MMSL
012839	NDDF
441532003	SNOMEDCT_US
441647003	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Vimpat	HUMAN PRESCRIPTION DRUG LABEL	1	0131-1810	INJECTION	10 mg	INTRAVENOUS	NDA	36 sections
Vimpat	HUMAN PRESCRIPTION DRUG LABEL	1	0131-2477	TABLET, FILM COATED	50 mg	ORAL	NDA	36 sections
Vimpat	HUMAN PRESCRIPTION DRUG LABEL	1	0131-2478	TABLET, FILM COATED	100 mg	ORAL	NDA	36 sections
Vimpat	HUMAN PRESCRIPTION DRUG LABEL	1	0131-2479	TABLET, FILM COATED	150 mg	ORAL	NDA	36 sections
Vimpat	HUMAN PRESCRIPTION DRUG LABEL	1	0131-2480	TABLET, FILM COATED	200 mg	ORAL	NDA	36 sections
Vimpat	HUMAN PRESCRIPTION DRUG LABEL	1	0131-5410	SOLUTION	10 mg	ORAL	NDA	36 sections
Vimpat	HUMAN PRESCRIPTION DRUG LABEL	1	54868-6077	TABLET, FILM COATED	50 mg	ORAL	NDA	32 sections
Lacosamide	Human Prescription Drug Label	1	63850-0053	TABLET, FILM COATED	50 mg	ORAL	ANDA	31 sections
Lacosamide	Human Prescription Drug Label	1	63850-0054	TABLET, FILM COATED	100 mg	ORAL	ANDA	31 sections
Lacosamide	Human Prescription Drug Label	1	63850-0055	TABLET, FILM COATED	150 mg	ORAL	ANDA	31 sections
Lacosamide	Human Prescription Drug Label	1	63850-0056	TABLET, FILM COATED	200 mg	ORAL	ANDA	31 sections
Lacosamide	HUMAN PRESCRIPTION DRUG LABEL	1	65162-912	SOLUTION	10 mg	ORAL	ANDA	20 sections
Vimpat	HUMAN PRESCRIPTION DRUG LABEL	1	70166-617	SOLUTION	10 mg	ORAL	NDA	34 sections